Cardio3, the leading Stem Cell Biotech gets a US patent on CAR-T

08/04/2015 - 2 minutes

Just a week after announcing its intention to launch an IPO in the United States, Cardio3 Biosciences continues increasing its presence in the States. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a significant patent application broadly covering TCR-deficient T-Cells engineered to express a chimeric antigen (CAR).

This patent application is the first allowed application in a series of filed patent applications augmenting the company’s protection for its allogeneic T-Cell technology. Cardio3 Biosciences (C3BS) has applied for additional patents related to this technology, which are in various phases of USPTO review. Allogeneic technology has the potential to optimize CAR T-Cell cancer immunotherapies by enabling the manufacturing of off-the-shelf cell products for the treatment of patients without the need for a genetic match.

 

Dr. Christian Homsy, CEO of Cardio3 BioSciences, commented: “We are extremely pleased to have received the Notice of Allowance from the USPTO for this patent application for TCR-deficient T-Cells engineered to express a CAR,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member